Role of metabolism and pharmacokinetic studies in the discovery of new drugs—present and future perspectives

References

• Atwal K. S., Swanson B. N., Unger S. E., Floyd D. M., Moreland S., Hedberg A., O'Reilly B. C. Dihydropyrimidine calcium channel blockers. 3. 3-Carbamoyl-4-aryl-1,2,3,4-tetrahydro-6-methyl-5-pyrimidine carboxylic acid esters as orally effective antihypertensive agents. Journal of Medicinal Chemistry 1991; 34: 806–811
   PubMed Web of Science ®Google Scholar
• Beresford A. P., Macrae P. V., Alker D., Kobylecki R. J. Biotransformation of Amlodipine. Arznein Forsch, Drug Research 1989; 39: 201–209
   PubMedGoogle Scholar
• Clark B., Smith D. A. Pharmacokinetics and toxicity testing. Critical Reviews in Toxicology 1984; 12: 343–385
   PubMed Web of Science ®Google Scholar
• Fromson J. M. A phased approach to drug development. Journal of Pharmacokinetics and Biopharmaceutics 1989; 17: 509–523
   PubMedGoogle Scholar
• Fouda H., Nocerini M., Schneider R., Gedutis. Quantitative analysis by high-performance liquid chromatography atmospheric pressure chemical ionisation mass spectrometry: the determination of the renin inhibitor CP-80, 794 in human serum. Journal of the American Society for Mass Spectrometry 1991; 2: 164–167
   PubMed Web of Science ®Google Scholar
• Gillard J. W., Bélanger P. Metabolic synthesis of arylacetic acid anti-inflammatory drugs from arylhexenoic acids. 2. Indomethacin. Journal of Medicinal Chemistry 1987; 30: 2051–2056
   PubMed Web of Science ®Google Scholar
• Gonzalez F. J. The molecular biology of cytochromes P450. Pharmacological Reviews 1989; 40: 243–277
   Web of Science ®Google Scholar
• Guengerich F. P., Distlerath L. M., Reilly P. E. B., Wolff T., Shimada T., Umbenhaur D. R., Martin M. V. Human-liver cytochromes P-450 involved in polymorphism of drug oxidation. Xenobiotica 1986; 16: 367–378
   PubMed Web of Science ®Google Scholar
• Humphrey M. J. Pharmacokinetic studies in the selection of new drugs—a case history on dihydropyridine calcium channel blockers. Xenobiotic Metabolism and Disposition, R. Kato, R. W. Estabrook, M. N. Cayen. Taylor & Francis, London 1989; 245–253
   Google Scholar
• Humphrey M. J., Jevons S., Tarbit M. H. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug in animals and man. Antimicrobial Agents and Chemotherapy 1985; 28: 648–653
   PubMed Web of Science ®Google Scholar
• Humphrey M. J., Ringrose P. S. Peptides and related drugs: a review of their absorption, metabolism and excretion. Drug Metabolism Reviews 1986; 17: 283–310
   PubMed Web of Science ®Google Scholar
• Kukolja S., Wright W. E., Quay J. F., Pfeil-Doyle J., Draheim S. E., Eudaly J. A., Johnson R. J., Ott J. L., Counter F. T., Cooper R. D. G., Cauvette R. R. Oral absorption of cephalosporin antiobitics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals. Journal of Medicinal Chemistry 1988; 31: 1987–1993
   PubMed Web of Science ®Google Scholar
• Lennard M. S., Tucker G. T., Silas J. H., Wood H. F. Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propanolol and atenolol. Xenobiotica 1986; 16: 435–447
   PubMed Web of Science ®Google Scholar
• Manoury P. M., Binet J. L., Rousseau J., Lefevre-Borg F. M., Carero I. G. Synthesis of a series of compounds related to Betaxolol, a new β1 adrenoceptor antagonist with a pharmacological and pharmacokinetic profile optimised for the treatment of chronic cardiovascular diseases. Journal of Medicinal Chemistry 1987; 30: 1003–1011
   PubMed Web of Science ®Google Scholar
• Mordenti J. Forecasting cephalosporin and monobactam antibiotic half-lives in humans from data collected in laboratory animals. Antimicrobial Agents and Chemotherapy 1985; 27: 587–891
   Web of Science ®Google Scholar
• Northridge D. B., Alabaster C. T., Connell J. M., Dilly S. G., Lever A. F., Jardine A. G., Barclay P. L., Dargie H. J., Findlay I. W., Samuels G. M. R. Effects of UK-69,578, a novel atriopeptidase inhibitor. Lancet 1989; ii: 591–593
   Google Scholar
• Notari R. Biopharmaceutics and Clinical Pharmacokinetics—an Introduction. Marcel Dekker Inc., New York 1987; 314
   Google Scholar
• Patchett A. A., Harris E., Tristram E. W., Wyvratt M. J., Wu M. T., Taub D., Peterson E. R., Ikeler T. J., ten Broeke J., Payne L. G., Ondeyka D. L., Thorsett E. D., Greenlee W. J., Lohr N. S., Hoffsommer R. D., Joshua H., Ruyle W. V., Rothrock J. W., Aster S. D., Maycock A. L., Robinson F. M., Hirschmann R., Sweet C. S., Ulm E. H., Gross D. M., Vassil T. C., Stone C. A. A new class of angiotensin-converting enzyme inhibitors. Nature 1980; 288: 280–283
   PubMed Web of Science ®Google Scholar
• Poulos T. L., Finzal B. C., Gunsalus I. C., Wagner G. C., Kraut J. The 2.6-AdR crystal structure of Pseudomonas putida cytochrome P-450. Journal of Biological Chemistry 1985; 260: 16122–16130
   PubMed Web of Science ®Google Scholar
• Prentis R. A., Lis Y., Walker S. R. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964–1985). British Journal of Clinical Pharmacology 1988; 25: 387–396
   PubMed Web of Science ®Google Scholar
• Rakhit A., Kuwahara S. K., Jones D. R., Soliman V. F., Kotake A. N., Oglesby T. D., Wasley J. W. F., Tripp S. F., Douglas F. L. Pharmacokinetic screening of O-napthoquinone 5-lipoxygenase inhibitors. Pharmaceutical Research 1990; 7: 1071–1076
   PubMed Web of Science ®Google Scholar
• Richardson K., Cooper K., Marriott M. S., Tarbit M. H., Troke P. F., Whittle P. J. Discovery of fluconazole, a novel antifungal agent. Reviews of Infectious Diseases 1990; 12(Suppl. 3)S267–271
   PubMedGoogle Scholar
• Robertson D. W., Leander J. D., Lawson R., Beedle E. E., Clark C. R., Potts B. D., Parli C. J. Discovery and anticonvulsant activity of the potent metabolic inhibitor 4-amino-N-(2,6 dimethylphenyl)-3,5-dimethylbenzamide. Journal of Medicinal Chemistry 1987; 30: 1742–1746
   PubMed Web of Science ®Google Scholar
• Rosenberg S. H., Kleinert H. D., Stein H. H., Martin D. L., Chekal M. A., Cohen J., Egan D. A., Tricarico K. A., Baker W. R. Design of a well-absorbed renin inhibitor. Journal of Medicinal Chemistry 1991; 34: 469–471
   PubMed Web of Science ®Google Scholar
• Rosenberg S. H., Woods K. W., Kleinert H. D., Stein H., Netlan S. H. N., Hoffman D. H., Spanton S. G., Pyter R. A., Cohen J., Egan D. A., Plattner H. H., Perun J. J. Azido glycols: potent, low molecular weight renin inhibitors containing an unusual post-scissile site residue. Journal of Medicinal Chemistry 1989; 32: 1371–1378
   PubMed Web of Science ®Google Scholar
• Rowland M., Tozer N. T. Clinical Pharmacokinetics—Concepts and Applications. Lea and Febiger, Philadelphia 1980
   Google Scholar
• Smith D. A. Species differences in metabolism and pharmacokinetics: are we close to an understanding?. Drug Metabolism Reviews 1991; 23: 255–274
   Web of Science ®Google Scholar
• Smith D. A., Beaumont K., Cussans N. J., Humphrey M. J., Jezequel S. J., Rance D. J., Stopher D. A., Walker D. K. Bioanalytical data in decision making: discovery and development. Xenobiotica 1992, in press
   Web of Science ®Google Scholar
• Smith D. A., Humphrey M. J., Charuel C. Design of toxicokinetic studies. Xenobiotica 1990; 20: 1185–1199
   Web of Science ®Google Scholar
• Swanson B., Stauber K. L., Alpaugh W. C., Weinstein S. H. Radioenzymatic assay of angiotensin-converting enzyme inhibitors in plasma and urine. Analytical Biochemistry 1985; 148: 401–407
   PubMed Web of Science ®Google Scholar
• Tarbit M. H. Pharmacokinetic aspects of antifungal therapy. Handbook of Experimental Pharmacology, Chemotherapy of Fungal Diseases, J. F. Ryley. Springer-Verlag, Berlin 1990; Vol. 96: 183–204
   Google Scholar
• Veber D. F., Payne L. S., Williams P. D., Perlow D. S., Lundell G. F., Gould N. P., Siegl P. K. S., Sweet C. S., Friedinger R. M. Design and discovery in the development of long-acting renin inhibitors. Biochemical Society Transactions 1990; 18: 1291–1294
   PubMed Web of Science ®Google Scholar